Skip to main content
. 2021 May;27(5):687–696. doi: 10.1016/j.cmi.2021.01.004

Fig. 3.

Fig. 3

Quality assessment according to the Newcastle-Ottawa scale of 286 studies evaluating the burden of drug-resistant infections in humans due to the WHO Global Antimicrobial Resistance Surveillance System (GLASS) priority resistant bacteria.